SCHEMBL3207269

SCHEMBL3207269

CC(C)c1nn2ccccc2c1-c1ccc(N2CCOCC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 7/20 0.47
PDE5A O76074 6/20 0.47
PDE3A Q14432 4/20 0.46
RAD51 Q06609 1/20 0.44
CFTR P13569 1/20 0.42
ALDH1A1 P00352 4/20 0.42
MAPT P10636 4/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
KDM4E B2RXH2 3/20 0.42
MEN1 O00255 2/20 0.42
CYP1A2 P05177 2/20 0.42
KMT2A Q03164 2/20 0.42
GAA P10253 2/20 0.42
MIF P14174 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3201178 0.78 PDE4B (0.54) PDE4BPDE5APDE3ARAD51ALDH1A1
SCHEMBL3202954 0.76 PDE4B (0.56) PDE4BPDE5APDE3AALDH1A1MEN1
SCHEMBL3197217 0.73 PDE4B (0.52) PDE4BPDE5APDE3AALDH1A1MEN1
SCHEMBL1269973 0.71 PDE4B (0.50) PDE4BPDE5APDE3AALDH1A1MEN1
SCHEMBL1269980 0.70 PDE4B (0.52) PDE4BPDE5APDE3AALDH1A1MEN1
SCHEMBL3194316 0.70 PDE4B (0.52) PDE4BPDE5APDE3ARAD51ALDH1A1
SCHEMBL3195918 0.70 PDE4B (0.52) PDE4BPDE5APDE3AALDH1A1MEN1
SCHEMBL4359398 0.69 PDE4B (0.51) PDE4BPDE5APDE3AALDH1A1MEN1
SCHEMBL3186177 0.69 PDE4B (0.51) PDE4BPDE5APDE3ARAD51ALDH1A1
SCHEMBL13484438 0.69 PDE4B (0.65) PDE4BPDE5APDE3AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2010-02-11 US disclosed
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2010-02-11 US disclosed
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2010-02-11 US disclosed
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE MEDICINOVA, INC. 2009-12-24 US disclosed
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE MEDICINOVA, INC. 2009-12-24 US disclosed
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE MEDICINOVA, INC. 2009-12-24 US disclosed
US-7585875-B2 Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use AVIGEN, INC. (US) 2009-09-08 US disclosed
US-7585875-B2 Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use AVIGEN, INC. (US) 2009-09-08 US disclosed
US-7585875-B2 Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use AVIGEN, INC. (US) 2009-09-08 US disclosed
EP-2038279-A2 SUBSTITUTED PYRAZOLO [1,5- ALPHA] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE Avigen, Inc. (US) 2009-03-25 EP disclosed
US-20080070912-A1 Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use AVIGEN, INC. (US) 2008-03-20 US disclosed
US-20080070912-A1 Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use AVIGEN, INC. (US) 2008-03-20 US disclosed
WO-2007146087-A2 SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE AVIGEN, INC. (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318437-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE PNPO, PDXK, CYP3A5 PDE4B 383/4885PDE5A 418/4885PDE3A 620/4885
US-20080070912-A1 Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use PNPO, PDXK, P2RX5 PDE4B 351/4885PDE5A 413/4885PDE3A 557/4885
US-20100035920-A1 SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE PNPO, PDXK, CYP3A5 PDE4B 383/4885PDE5A 418/4885PDE3A 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.